These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18351427)

  • 21. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
    Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
    Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determinants of persistence with weekly bisphosphonates in patients with osteoporosis.
    Jones TJ; Petrella RJ; Crilly R
    J Rheumatol; 2008 Sep; 35(9):1865-73. PubMed ID: 18709688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of treatment benefit due to low compliance with bisphosphonate therapy.
    Penning-van Beest FJ; Erkens JA; Olson M; Herings RM
    Osteoporos Int; 2008 Apr; 19(4):511-7. PubMed ID: 17874028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
    Gold DT; Trinh H; Safi W
    Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
    McHorney CA; Schousboe JT; Cline RR; Weiss TW
    Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study.
    de Lusignan S; van Vlymen J; Hague N; Dhoul N
    Osteoporos Int; 2006 Dec; 17(12):1808-14. PubMed ID: 16932873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.
    Durden E; Pinto L; Lopez-Gonzalez L; Juneau P; Barron R
    Arch Osteoporos; 2017 Dec; 12(1):22. PubMed ID: 28243883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
    Gold DT; Safi W; Trinh H
    Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.
    Gold DT; Bonnick SL; Amonkar MM; Kamel HK; Agarwal S; Zaidi M
    Gend Med; 2008 Dec; 5(4):374-84. PubMed ID: 19108810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.
    Burden AM; Paterson JM; Solomon DH; Mamdani M; Juurlink DN; Cadarette SM
    Osteoporos Int; 2012 Mar; 23(3):1075-82. PubMed ID: 21604008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors contributing to compliance with osteoporosis medication.
    Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N
    Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
    Lai PS; Chua SS; Chew YY; Chan SP
    J Clin Pharm Ther; 2011 Oct; 36(5):557-67. PubMed ID: 21916908
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of combined oral bisphosphonate therapy and falls prevention exercise for fracture prevention in the USA.
    Mori T; Crandall CJ; Ganz DA
    Osteoporos Int; 2017 Feb; 28(2):585-595. PubMed ID: 27726000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases.
    Brankin E; Walker M; Lynch N; Aspray T; Lis Y; Cowell W
    Curr Med Res Opin; 2006 Jul; 22(7):1249-56. PubMed ID: 16834823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship Between Gastrointestinal Events and Compliance With Osteoporosis Therapy: An Administrative Claims Analysis of the US Managed Care Population.
    Modi A; Sajjan S; Michael Lewiecki E; Harris ST; Papadopoulos Weaver J
    Clin Ther; 2016 May; 38(5):1074-80. PubMed ID: 27112533
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compliance with drug therapy for postmenopausal osteoporosis.
    Weycker D; Macarios D; Edelsberg J; Oster G
    Osteoporos Int; 2006; 17(11):1645-52. PubMed ID: 16862397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan.
    Moriwaki K; Mouri M; Hagino H
    Osteoporos Int; 2017 Jun; 28(6):1939-1950. PubMed ID: 28265718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
    Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
    Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.
    Fleurence RL; Iglesias CP; Johnson JM
    Pharmacoeconomics; 2007; 25(11):913-33. PubMed ID: 17960951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medication persistence and risk of fracture among female Medicare beneficiaries diagnosed with osteoporosis.
    Liu J; Guo H; Rai P; Pinto L; Barron R
    Osteoporos Int; 2018 Nov; 29(11):2409-2417. PubMed ID: 30022254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.